NASDAQ:FEMY Femasys Q3 2026 Earnings Results & Report $1.12 -0.16 (-12.50%) Closing price 04:00 PM EasternExtended Trading$1.14 +0.02 (+1.79%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Femasys beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.53 versus the -$0.6050 consensus estimate, while revenue of $404.60 thousand fell short of the $620 thousand estimate by $215.40 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 13, 2026TimeAfter Market ClosesConference Call7:00 AM ET Femasys EPS ResultsActual EPS-$0.53Consensus EPS -$0.6050Beat/MissBeat by +$0.0750One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersFemasys Revenue ResultsActual Revenue$404.60 thousandExpected Revenue$620 thousandBeat/MissMissed by -$215.40 thousandYoY Revenue GrowthN/AUpcoming EarningsFemasys' Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 20, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Femasys Q3 2026 Earnings FAQ Did Femasys beat earnings estimates for Q3 2026? Femasys (NASDAQ:FEMY) reported earnings of -$0.53 per share for Q3 2026, beating the consensus estimate of -$0.6050. The report was announced on Friday, November 13, 2026. What was Femasys' revenue for Q3 2026? Femasys reported revenue of $404.60 thousand for Q3 2026, against a consensus estimate of $620 thousand. When is Femasys' next earnings date? Femasys' next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Femasys on the company's earnings history page. Femasys Earnings HeadlinesFemasys (NASDAQ:FEMY) Stock Rating Upgraded by Wall Street ZenNovember 16 at 1:07 AM | americanbankingnews.comFemasys Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 13, 2026 | quiverquant.comQLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for $29.97, but it's available as a free download for a limited time.November 17 at 1:00 AM | Profits Run (Ad)Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate UpdateNovember 13, 2026 | globenewswire.comFemasys (NASDAQ:FEMY) Cut to Strong Sell at Wall Street ZenNovember 8, 2026 | americanbankingnews.comFemasys Inc. Appoints John Moorhead to Board of Directors as Commercialization Efforts AdvanceOctober 30, 2026 | quiverquant.comQSee More Femasys Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email. Email Address About FemasysFemasys (NASDAQ:FEMY) is a medical technology company focused on developing and commercializing products for women’s health, with an emphasis on fertility and contraception. Founded in 2004 and headquartered in Georgia, the company aims to provide minimally invasive options for reproductive care. Its products include FemVue, a system used with ultrasound to evaluate whether a woman’s fallopian tubes are open, and FemaSeed, a device designed to deliver sperm closer to the site of fertilization during insemination. Femasys is also developing FemBloc, a non-surgical approach to permanent contraception. Founder Kathy Lee-Sepsick serves as the company’s chief executive officer. Femasys is based in the United States and has pursued commercial and regulatory opportunities in domestic and international markets.View Femasys ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.